Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) were down 1.8% on Friday . The stock traded as low as $1.62 and last traded at $1.68. Approximately 275,347 shares were traded during mid-day trading, a decline of 28% from the average daily volume of 379,802 shares. The stock had previously closed at $1.71.

Several analysts recently weighed in on ANTH shares. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Anthera Pharmaceuticals in a research note on Tuesday, September 19th. Jefferies Group LLC reiterated a “hold” rating and set a $1.75 target price (down from $2.25) on shares of Anthera Pharmaceuticals in a research note on Friday, August 11th. Finally, Zacks Investment Research downgraded Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. Anthera Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $5.89.

The firm’s market cap is $17.99 million. The company’s 50 day moving average is $1.44 and its 200 day moving average is $1.36.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $1.12. Analysts anticipate that Anthera Pharmaceuticals, Inc. will post ($3.68) earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its holdings in Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 335,595 shares during the last quarter. Sabby Management LLC grew its holdings in Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 1,665,655 shares during the last quarter. Finally, UBS Group AG grew its holdings in Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 33,901 shares during the last quarter. 27.26% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Anthera Pharmaceuticals, Inc. (ANTH) Trading Down 1.8%” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/10/08/anthera-pharmaceuticals-inc-anth-trading-down-1-8.html.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.